Login to Your Account



Pharma Companies Overlook Patent Cliff, but Don't Fall Yet

By Staff Reports


Monday, October 29, 2012
Merck & Co. Inc., of Whitehouse Station, N.J., shrugged off the worst effects of the August 2012 loss of market exclusivity for its blockbuster drug Singulair (montelukast sodium) in the U.S.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription